Market PenetrationINSP holds the dominant share in the fast-growing, $10B US hypoglossal nerve stim market for OSA, with only 5% penetration, representing a vast market opportunity.
Product AdvantageINSP's minimally invasive, closed-loop neurostimulator maximizes patient comfort and compliance, outperforming other OSA treatments.
Stock ValuationAnalyst maintains a Buy rating with a price objective of 265.00 USD, indicating significant upside potential.